S.C. Ropharma Statistics

Total Valuation

S.C. Ropharma has a market cap or net worth of RON 77.71 million. The enterprise value is 234.35 million.

Market Cap	77.71M
Enterprise Value	234.35M

Important Dates

The last earnings date was Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	n/a

Share Statistics

S.C. Ropharma has 511.27 million shares outstanding.

Current Share Class	511.27M
Shares Outstanding	511.27M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-3.52%
Owned by Insiders (%)	23.68%
Owned by Institutions (%)	n/a
Float	279.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.06
PB Ratio	0.30
P/TBV Ratio	0.42
P/FCF Ratio	2.41
P/OCF Ratio	1.80
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.42, with an EV/FCF ratio of 7.26.

EV / Earnings	-135.78
EV / Sales	0.18
EV / EBITDA	4.42
EV / EBIT	9.60
EV / FCF	7.26

Financial Position

The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.63.

Current Ratio	1.05
Quick Ratio	0.62
Debt / Equity	0.63
Debt / EBITDA	3.06
Debt / FCF	5.03
Interest Coverage	4.17

Financial Efficiency

Return on equity (ROE) is 2.10% and return on invested capital (ROIC) is 3.64%.

Return on Equity (ROE)	2.10%
Return on Assets (ROA)	1.74%
Return on Invested Capital (ROIC)	3.64%
Return on Capital Employed (ROCE)	6.48%
Revenue Per Employee	767,946
Profits Per Employee	-1,002
Employee Count	894
Asset Turnover	1.51
Inventory Turnover	5.18

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.74% in the last 52 weeks. The beta is 0.17, so S.C. Ropharma's price volatility has been lower than the market average.

Beta (5Y)	0.17
52-Week Price Change	-17.74%
50-Day Moving Average	0.15
200-Day Moving Average	0.17
Relative Strength Index (RSI)	48.62
Average Volume (20 Days)	59,079

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, S.C. Ropharma had revenue of RON 1.32 billion and -1.73 million in losses. Loss per share was -0.00.

Revenue	1.32B
Gross Profit	292.79M
Operating Income	24.42M
Pretax Income	21.55M
Net Income	-1.73M
EBITDA	41.19M
EBIT	24.42M
Loss Per Share	-0.00

Full Income Statement

Balance Sheet

The company has 19.90 million in cash and 162.42 million in debt, giving a net cash position of -142.52 million or -0.28 per share.

Cash & Cash Equivalents	19.90M
Total Debt	162.42M
Net Cash	-142.52M
Net Cash Per Share	-0.28
Equity (Book Value)	259.34M
Book Value Per Share	0.48
Working Capital	30.67M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 43.16 million and capital expenditures -10.87 million, giving a free cash flow of 32.29 million.

Operating Cash Flow	43.16M
Capital Expenditures	-10.87M
Free Cash Flow	32.29M
FCF Per Share	0.06

Full Cash Flow Statement

Margins

Gross margin is 22.13%, with operating and profit margins of 1.85% and -0.13%.

Gross Margin	22.13%
Operating Margin	1.85%
Pretax Margin	1.63%
Profit Margin	-0.13%
EBITDA Margin	3.11%
EBIT Margin	1.85%
FCF Margin	2.44%

Dividends & Yields

S.C. Ropharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-2.22%
FCF Yield	41.55%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

S.C. Ropharma has an Altman Z-Score of 1.8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.8
Piotroski F-Score	n/a